Page last updated: 2024-11-11

epicinchonine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

epicinchonine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cinchonine : Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (S configuration). It occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5702153
CHEMBL ID3039381
CHEBI ID92258
SCHEMBL ID13587301
SCHEMBL ID4575680
MeSH IDM0355180

Synonyms (57)

Synonym
BRD-K18476269-001-02-9
KBIO1_000237
DIVK1C_000237
SDCCGMLS-0066951.P001
SPECTRUM_000061
BSPBIO_002226
SPECTRUM5_001566
NCGC00178751-01
118-10-5
cinchonine
KBIOGR_001365
KBIO3_001726
KBIO2_000461
KBIOSS_000461
KBIO2_005597
KBIO2_003029
SPBIO_000468
SPECTRUM3_000633
SPECTRUM4_000823
SPECTRUM2_000594
NINDS_000237
SPECTRUM1500841
IDI1_000237
HMS2092M16
HMS500L19
(r)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol
HMS1921K16
unii-35ve0jqr6n
cinchonan-9-ol, (9r)
epicinchonine
485-70-1
9-epi-cinchonine
35ve0jqr6n ,
9-epicinchonine
CHEMBL3039381
nsc-757801
nsc757801
pharmakon1600-01500841
CCG-39753
(r)-quinolin-4-yl((1s,2r,4s,5r)-5-vinylquinuclidin-2-yl)methanol
cinchonine epicinchonine
cinchonine epicinchonine [mi]
epi-cinchonine
SCHEMBL13587301
SCHEMBL4575680
AB01563191_01
CHEBI:92258
SR-05000001576-2
SR-05000001576-1
sr-05000001576
SBI-0051618.P002
AS-52656
Q27164023
DTXSID00859217
BRD-K14693417-001-03-2
P15458
(r)-[(1s,2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](quinolin-4-yl)methanol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively)."( Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance.
Belon, JP; Chauffert, B; Duchamp, O; Genne, P; Magnette, J; Solary, E, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinchona alkaloidAn alkaloid based on a cinchonan skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (22.50)18.7374
1990's14 (17.50)18.2507
2000's19 (23.75)29.6817
2010's20 (25.00)24.3611
2020's9 (11.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (9.20%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (90.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]